
## Vicki L Ellingrod

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1576032/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacogenetics of Methadone for Pain Management in Palliative Care. Journal of Pain and Symptom Management, 2022, 63, e142-e145.	0.6	1
2	Psychiatrist and Psychiatric Pharmacists Beliefs and Preferences for Atypical Antipsychotic Treatments in Patients With Schizophrenia and Bipolar Disorders. Journal of Pharmacy Practice, 2021, 34, 78-88.	0.5	2
3	Use of psychiatric medication by college students: A decade of data. Pharmacotherapy, 2021, 41, 350-358.	1.2	11
4	Pharmacogenomic testing for mental health (Part I): documenting early adopter perceptions of use for eight scenarios. Personalized Medicine, 2021, 18, 223-232.	0.8	1
5	Genetic and Metabolite Variability in One-Carbon Metabolism Applied to an Insulin Resistance Model in Patients With Schizophrenia Receiving Atypical Antipsychotics. Frontiers in Psychiatry, 2021, 12, 623143.	1.3	2
6	Pharmacogenomic testing for mental health (Part II): qualitative analysis of early adopter prescriber prescrib	0.8	0
7	Sexual Functioning in Adolescents With Major Depressive Disorder. Journal of Clinical Psychiatry, 2021, 82, .	1.1	2
8	Could Dietary Glutamate Play a Role in Psychiatric Distress?. Neuropsychobiology, 2020, 79, 13-19.	0.9	21
9	Establishment of a Pharmacogenetics Service Focused on Optimizing Existing Pharmacogenetic Testing at a Large Academic Health Center. Journal of Personalized Medicine, 2020, 10, 154.	1.1	12
10	Dietary Glutamic Acid, Obesity, and Depressive Symptoms in Patients With Schizophrenia. Frontiers in Psychiatry, 2020, 11, 620097.	1.3	12
11	Metabolic syndrome is negatively associated with cognition among endothelial nitric oxide synthase (eNOS)- 786C carriers in schizophrenia-spectrum disorders. Journal of Psychiatric Research, 2019, 117, 142-147.	1.5	2
12	3143 DIAMOND: A Digital Platform for Workforce Development. Journal of Clinical and Translational Science, 2019, 3, 67-67.	0.3	0
13	The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis. Schizophrenia Bulletin, 2019, 45, 1170-1183.	2.3	44
14	Assessments of Research Competencies for Clinical Investigators: A Systematic Review. Evaluation and the Health Professions, 2019, 44, 016327871989639.	0.9	6
15	Effects of Atypical Antipsychotic Treatment and Resistant Starch Supplementation on Gut Microbiome Composition in a Cohort of Patients with Bipolar Disorder or Schizophrenia. Pharmacotherapy, 2019, 39, 161-170.	1.2	81
16	Patient perspectives on medication self-management in rural Kenya: a cross-sectional survey. International Journal for Quality in Health Care, 2019, 31, 353-358.	0.9	5
17	Using Pharmacogenomic Testing in Primary Care: Protocol for a Pilot Randomized Controlled Study. JMIR Research Protocols, 2019, 8, e13848.	0.5	1
18	Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia. Pharmacotherapy, 2018, 38, 638-650.	1.2	11

#	Article	IF	CITATIONS
19	Eye gaze perception in bipolar disorder: Selfâ€referential bias but intact perceptual sensitivity. Bipolar Disorders, 2018, 20, 60-69.	1.1	17
20	A Bayesian model comparison approach to test the specificity of visual integration impairment in schizophrenia or psychosis. Psychiatry Research, 2018, 265, 271-278.	1.7	8
21	The Influence of Metabolic Syndrome and Sex on the DNA Methylome in Schizophrenia. International Journal of Genomics, 2018, 2018, 1-12.	0.8	15
22	Competency indices to assess the knowledge, skills and abilities of clinical research professionals. International Journal of Clinical Trials, 2018, 5, 46.	0.0	15
23	Supplemental Use of Complementary Alternative Medicine for the Treatment of Schizophrenia. Psychiatric Annals, 2018, 48, 211-213.	0.1	0
24	Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia. Pharmacotherapy, 2017, 37, 1122-1130.	1.2	15
25	Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort. Pharmacotherapy, 2017, 37, 261-267.	1.2	207
26	Precision Pharmacotherapy Enables Precision Medicine. Pharmacotherapy, 2017, 37, 985-987.	1.2	5
27	Germline genetic variants with implications for disease risk and therapeutic outcomes. Physiological Genomics, 2017, 49, 567-581.	1.0	8
28	Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy. Pharmacogenomics, 2017, 18, .	0.6	2
29	Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers. AAPS Journal, 2017, 19, 1513-1522.	2.2	21
30	Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar Disorder. Clinical Schizophrenia and Related Psychoses, 2017, 11, 39-48.	1.4	25
31	Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders. Psychopharmacology Bulletin, 2017, 47, 8-21.	0.0	11
32	Geneâ€specific <scp>DNA</scp> methylation may mediate atypical antipsychoticâ€induced insulin resistance. Bipolar Disorders, 2016, 18, 423-432.	1.1	27
33	Oxytocin Receptor <b><i>(OXTR)</i></b> Methylation and Cognition in Psychotic Disorders. Molecular Neuropsychiatry, 2016, 2, 151-160.	3.0	15
34	Identification of nonâ€reported bupropion metabolites in human plasma. Biopharmaceutics and Drug Disposition, 2016, 37, 550-560.	1.1	10
35	Negative affect predicts social functioning across schizophrenia and bipolar disorder: Findings from an integrated data analysis. Psychiatry Research, 2016, 243, 198-206.	1.7	26
36	Interaction between COMT rs5993883 and second generation antipsychotics is linked to decreases in verbal cognition and cognitive control in bipolar disorder. BMC Psychology, 2016, 4, 14.	0.9	13

#	Article	IF	CITATIONS
37	An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar Disorder. Clinical and Translational Science, 2015, 8, 432-440.	1.5	25
38	The effect of folate supplementation and genotype on cardiovascular and epigenetic measures in schizophrenia subjects. NPJ Schizophrenia, 2015, 1, 15046.	2.0	16
39	The Microbiome in Mental Health: Potential Contribution of Gut Microbiota in Disease and Pharmacotherapy Management. Pharmacotherapy, 2015, 35, 910-916.	1.2	42
40	The development of depressive symptoms during medical internship stress predicts worsening vascular function. Journal of Psychosomatic Research, 2015, 79, 243-245.	1.2	11
41	DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder. Epigenomics, 2015, 7, 343-352.	1.0	29
42	Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders. Schizophrenia Research, 2015, 164, 115-121.	1.1	13
43	Team-Based Learning to Improve Learning Outcomes in a Therapeutics Course Sequence. American Journal of Pharmaceutical Education, 2014, 78, 13.	0.7	41
44	Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics. Pharmacogenomics, 2014, 15, 61-67.	0.6	12
45	Effects of Cigarette Smoking on Metabolism and Effectiveness of Systemic Therapy for Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 917-926.	0.5	99
46	Vitamin D Receptor Genetics on Extracellular Matrix Biomarkers and Hemodynamics in Systolic Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 439-445.	1.0	13
47	Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. Bipolar Disorders, 2014, 16, 277-288.	1.1	77
48	Detection of Metabolic Syndrome in Schizophrenia and Implications for Antipsychotic Therapy. Molecular Diagnosis and Therapy, 2013, 17, 21-30.	1.6	25
49	P-glycoprotein (PGP) Polymorphisms and Sexual Dysfunction in Female Patients With Depression and SSRI-Associated Sexual Side Effects. Journal of Sex and Marital Therapy, 2013, 39, 280-288.	1.0	19
50	Fatty Acid Desaturase Gene Polymorphisms and Metabolic Measures in Schizophrenia and Bipolar Patients Taking Antipsychotics. Cardiovascular Psychiatry and Neurology, 2013, 2013, 1-8.	0.8	16
51	A Pilot Study Investigating Tumor Necrosis Factor-α as a Potential Intervening Variable of Atypical Antipsychotic–Associated Metabolic Syndrome in Bipolar Disorder. Therapeutic Drug Monitoring, 2013, 35, 194-202.	1.0	11
52	Genetic Variations in TGFβ1, tPA, and ACE and Radiation-Induced Thoracic Toxicities in Patients with Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 208-213.	0.5	19
53	759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment. Clinical Pharmacology & Biopharmaceutics, 2013, 02, 110.	0.2	12
54	Atypical antipsychotics attenuate associations between linoleic acid and reduced markers of metabolic syndrome. FASEB Journal, 2013, 27, 1067.5.	0.2	0

#	Article	IF	CITATIONS
55	Risk Factors Associated With Metabolic Syndrome in Bipolar and Schizophrenia Subjects Treated With Antipsychotics. Journal of Clinical Psychopharmacology, 2012, 32, 261-265.	0.7	76
56	Cryptochrome 2 variants, chronicity, and seasonality of mood disorders. Psychiatric Genetics, 2012, 22, 305-306.	0.6	12
57	DNA methylation in schizophrenia subjects: gender and <i>MTHFR</i> 677C/T genotype differences. Epigenomics, 2012, 4, 261-268.	1.0	45
58	Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Current Psychiatry Reviews, 2012, 8, 25-36.	0.9	63
59	Association of plasma omega-3 and omega-6 lipids with burden of disease measures in bipolar subjects. Journal of Psychiatric Research, 2012, 46, 1435-1441.	1.5	25
60	Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction. Psychiatry Research, 2012, 199, 74-76.	1.7	16
61	Fats and Factors: Lipid Profiles Associate with Personality Factors and Suicidal History in Bipolar Subjects. PLoS ONE, 2012, 7, e29297.	1.1	31
62	Schizophrenia and folate pharmacogenetics: Review of the literature regarding folic acid and its pharmacogenetically regulated metabolism in relation to schizophrenia treatments. Mental Health Clinician, 2012, 1, 225-229.	0.5	1
63	Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs). Schizophrenia Research, 2011, 130, 20-26.	1.1	34
64	Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry Research, 2011, 187, 74-79.	1.7	19
65	Factors Associated with the Prescribing of Olanzapine, Quetiapine, and Risperidone in Patients with Bipolar and Related Affective Disorders. Pharmacotherapy, 2011, 31, 806-812.	1.2	12
66	Association between typeâ€ŧhree metabotropic glutamate receptor gene ( <i>GRM3</i> ) variants and symptom presentation in treatment refractory schizophrenia. Human Psychopharmacology, 2011, 26, 28-34.	0.7	24
67	Anxiety, Depression, and Cognitive Impairment in Dementia-Specific and Traditional Assisted Living. Journal of Gerontological Nursing, 2010, 36, 18-30.	0.3	14
68	A pilot study of the pharmacodynamic impact of SSRI drug selection and beta-1 receptor genotype (ADRB1) on cardiac vital signs in depressed patients: a novel pharmacogenetic approach. Psychopharmacology Bulletin, 2010, 43, 11-22.	0.0	6
69	Introduction to the College of Psychiatric and Neurologic Pharmacists 2009 Poster Abstracts. Journal of Pharmacy Practice, 2009, 22, 202-202.	0.5	0
70	The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)â€∎ssociated sexual side effects: possible relationship to oral contraceptives. Human Psychopharmacology, 2009, 24, 207-215.	0.7	49
71	Leptin Gene –2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatric Genetics, 2009, 19, 320-327.	0.6	47
72	Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophrenia Research, 2008, 98, 47-54.	1.1	93

#	Article	IF	CITATIONS
73	Tales from the field: what the nursing research textbooks will not tell you. Applied Nursing Research, 2008, 21, 232-236.	1.0	3
74	Dementia-Specific Assisted Living: Clinical Factors and Psychotropic Medication Use. Journal of the American Psychiatric Nurses Association, 2008, 14, 39-49.	0.4	10
75	Dementia Care in Assisted Living: Needs and Challenges. Issues in Mental Health Nursing, 2008, 29, 817-838.	0.6	14
76	Metabotropic Glutamate Receptor Genes as Candidates for Pharmacogenetic Studies of Current and Future Antipsychotic Agents in Schizophrenia. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2007, 5, 21-30.	0.3	2
77	Introduction To Pharmacogenomics. Journal of Pharmacy Practice, 2007, 20, 203-205.	0.5	2
78	Incorporating Pharmacogenomics into Practice. Journal of Pharmacy Practice, 2007, 20, 277-282.	0.5	10
79	Pharmacogenomics in Psychiatry. Journal of Pharmacy Practice, 2007, 20, 252-264.	0.5	2
80	LA allelic heterozygosity of the 5HTTLPR polymorphism is associated with higher cognitive function and lower interpersonal sensitivity. Psychiatric Genetics, 2007, 17, 3-4.	0.6	16
81	Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatric Genetics, 2007, 17, 358.	0.6	17
82	Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacology Bulletin, 2007, 40, 57-62.	0.0	62
83	The Relationship Between P-Glycoprotein (PGP) Polymorphisms and Response to Olanzapine Treatment in Schizophrenia. Therapeutic Drug Monitoring, 2006, 28, 668-672.	1.0	51
84	Serotonin 2A â~'1438 G/A and G-Protein Beta3 Subunit C825T Polymorphisms in Patients with Depression and SSRI-Associated Sexual Side-Effects. Neuropsychopharmacology, 2006, 31, 2281-2288.	2.8	90
85	The Association of Weight Gain and Olanzapine Plasma Concentrations. Journal of Clinical Psychopharmacology, 2005, 25, 250-254.	0.7	45
86	Phobic anxiety in late-life in relationship to cognition and 5HTTLPR polymorphism. Psychiatric Genetics, 2005, 15, 305-306.	0.6	18
87	Weight gain associated with the ?759C/T polymorphism of the 5HT2C receptor and olanzapine. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 134B, 76-78.	1.1	133
88	Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophrenia Research, 2005, 77, 253-260.	1.1	78
89	Pooled Analysis of Antidepressant Levels in Lactating Mothers, Breast Milk, and Nursing Infants. American Journal of Psychiatry, 2004, 161, 1066-1078.	4.0	274
90	Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response. Pharmacogenomics, 2004, 5, 463-477.	0.6	10

#	Article	IF	CITATIONS
91	Distribution of the serotonin 2C (5HT2C) receptor gene â^'759C/T polymorphism in patients with schizophrenia and normal controls. Psychiatric Genetics, 2004, 14, 93-95.	0.6	8
92	CYP3A5 Polymorphism and the Ethnic Differences in Cyclosporine Pharmacokinetics in Healthy Subjects 1. Therapeutic Drug Monitoring, 2004, 26, 524-528.	1.0	67
93	Association of the CYP3A4*1B 5´-Flanking Region Polymorphism With Cyclosporine Pharmacokinetics in Healthy Subjects. Therapeutic Drug Monitoring, 2003, 25, 305-309.	1.0	53
94	The Influence of Cognitive Impairment and Behavioral Dysregulation on Daily Functioning in the Nursing Home Setting. American Journal of Psychiatry, 2003, 160, 582-584.	4.0	20
95	5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacology Bulletin, 2003, 37, 109-12.	0.0	28
96	CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatric Genetics, 2002, 12, 55-58.	0.6	65
97	C3435T Mutation in Exon 26 of the Human MDR1 Gene and Cyclosporine Pharmacokinetics in Healthy Subjects. Therapeutic Drug Monitoring, 2002, 24, 400-404.	1.0	84
98	Comparison of Risperidone with Olanzapine in Elderly Patients with Dementia and Psychosis. Pharmacotherapy, 2002, 22, 1-5.	1.2	32
99	Abnormal Movements and Tardive Dyskinesia in Smokers and Nonsmokers with Schizophrenia Genotyped for Cytochrome P450 2D6. Pharmacotherapy, 2002, 22, 1416-1419.	1.2	28
100	5HT2A and 5HT2C Receptor Polymorphisms And Predicting Clinical Response to Olanzapine in Schizophrenia. Journal of Clinical Psychopharmacology, 2002, 22, 622-624.	0.7	36
101	The Influence of Cognitive Impairment and Psychiatric Symptoms on Daily Functioning in Nursing Facilities: A Longitudinal Study. Annals of Clinical Psychiatry, 2002, 14, 209-213.	0.6	13
102	Caregiver Report of Hallucinations and Paranoid Delusions in Elders Aged 70 or Older. International Psychogeriatrics, 2001, 13, 241-249.	0.6	20
103	Lack of menstrual cycle effects on hypothalamic- pituitary-adrenal axis response to insulin-induced hypoglycaemia. Clinical Endocrinology, 2000, 52, 781-787.	1.2	9
104	Pharmacogenetic Screening for Susceptibility to Fetal Malformations in Women. Annals of Pharmacotherapy, 2000, 34, 639-645.	0.9	16
105	Psychosexual effects of three doses of testosterone cycling in normal men. Biological Psychiatry, 1999, 45, 254-260.	0.7	122
106	The Effects of Anabolic Steroids on Driving Performance as Assessed by the Iowa Driver Simulator. American Journal of Drug and Alcohol Abuse, 1997, 23, 623-636.	1.1	18
107	Venlafaxine: A heterocyclic antidepressant. American Journal of Health-System Pharmacy, 1994, 51, 3033-3046.	0.5	3